| Literature DB >> 26221416 |
J Gambini1, M Inglés2, G Olaso1, R Lopez-Grueso3, V Bonet-Costa1, L Gimeno-Mallench1, C Mas-Bargues1, K M Abdelaziz1, M C Gomez-Cabrera1, J Vina1, C Borras1.
Abstract
Plants containing resveratrol have been used effectively in traditional medicine for over 2000 years. It can be found in some plants, fruits, and derivatives, such as red wine. Therefore, it can be administered by either consuming these natural products or intaking nutraceutical pills. Resveratrol exhibits a wide range of beneficial properties, and this may be due to its molecular structure, which endow resveratrol with the ability to bind to many biomolecules. Among these properties its activity as an anticancer agent, a platelet antiaggregation agent, and an antioxidant, as well as its antiaging, antifrailty, anti-inflammatory, antiallergenic, and so forth activities, is worth highlighting. These beneficial biological properties have been extensively studied in humans and animal models, both in vitro and in vivo. The issue of bioavailability of resveratrol is of paramount importance and is determined by its rapid elimination and the fact that its absorption is highly effective, but the first hepatic step leaves little free resveratrol. Clarifying aspects like stability and pharmacokinetics of resveratrol metabolites would be fundamental to understand and apply the therapeutic properties of resveratrol.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26221416 PMCID: PMC4499410 DOI: 10.1155/2015/837042
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Figure 1Chemical structures of trans-resveratrol and cis-resveratrol.
Figure 2Resveratrol metabolites.
Figure 3Comparison of the chemical structures of trans-resveratrol and 17-β-estradiol.
(a) Clinical trials (humans)
| Article | Study type | Administered dose | Treatment time | Blood resveratrol | Dietary dose | Relevance |
|---|---|---|---|---|---|---|
| [ |
| Oral: 25 mg; intravenous: 1.5 mg | Once | <5 ng/mL | NO | Resveratrol is quickly metabolized |
|
| ||||||
| [ |
| Oral: 25 mg | Once | 10 to 40 nmol/L | NO |
|
|
| ||||||
| [ |
| Diet: | Once | Not detected | YES | The observed protective effect on cardiovascular diseases associated with a moderate consumption of wine may be due to the whole polyphenols contained in wine and not to resveratrol alone |
|
| ||||||
| [ |
| Oral: 2 times/day 2000 mg | 16 days | 1274 ± 790 ng/mL | NO | A high-fat meal decreases resveratrol absorption |
|
| ||||||
| [ |
| Oral: 1 g | Once | NO | A rapid, sensitive, and accurate method for the analysis of resveratrol and its metabolites in human plasma and urine | |
|
| ||||||
| [ |
| Oral: 6 times/day | Two days | 3.89 ng/mL | NO | Repeated administration was well-tolerated but produced relatively low plasma concentrations of |
|
| ||||||
| [ |
| Wine in diet | YES | A moderate wine consumption (alcohol) may be one explanation for protection from coronary heart disease | ||
|
| ||||||
| [ |
| Oral: | 28 days | NO | Resveratrol improves insulin sensitivity in subjects with impaired glucose tolerance | |
|
| ||||||
| [ |
| 150 mg/day | 30 days | 182.59 ± 30.33 ng/mL | NO | Resveratrol supplementation induces metabolic changes in obese humans, mimicking the effects of calorie restriction |
(b) In vivo (animals)
| Article | Study type | Administered dose | Treatment time | Relevance |
|---|---|---|---|---|
| [ |
| Oral: 200 | 100 days | A protective role of resveratrol in colon carcinogenesis. |
|
| ||||
| [ |
| Orally or intraperitoneally: | 16 weeks | Resveratrol may be a promising natural anticarcinogenesis agent for the prevention and treatment of human esophageal cancer |
|
| ||||
| [ |
| Diet: 200 | 120 days | Resveratrol suppresses 7,12-dimethylbenz(a)anthracene induced mammary carcinogenesis |
|
| ||||
| [ |
| Oral or subcutaneous: | Weak estrogenicity of the red wine constituent resveratrol | |
|
| ||||
| [ |
| Oral: 1, 4, 10, 40, and 100 | Six days | Resveratrol has little or no estrogen agonism on reproductive and nonreproductive estrogen target tissues and may be an estrogen antagonist |
|
| ||||
| [ |
| Oral: 0.75 mg/kg | Eight weeks | Resveratrol improves energy metabolism and reduces protein wasting |
|
| ||||
| [ |
| Oral: 4 mg/kg/day | 12 weeks | Resveratrol inhibits platelet aggregation |
|
| ||||
| [ |
| Diet: 200 mg/kg/day | 21 months | Resveratrol affects insulin sensitivity by improving glucose tolerance |
|
| ||||
| [ |
| Diet: 100 | Whole life | Resveratrol activates sirtuins in |
|
| ||||
| [ |
| Diet: 50–500 | Whole life | Resveratrol extends lifespan |
|
| ||||
| [ |
| Diet: 100–1000 | Whole life | Lifespan extension in |
|
| ||||
| [ |
| Diet: 30–130 | Whole life | Resveratrol significantly affects gustatory responsiveness and prolongs lifespan under normal oxygen conditions |
(c) In vitro
| Article | Study type | Administered dose | Relevance |
|---|---|---|---|
| [ |
| 3–10 | Resveratrol exhibits variable degrees of estrogen receptor agonism in different test systems |
|
| |||
| [ |
| 25 | Resveratrol negatively modulates prostate cancer cell growth |
|
| |||
| [ |
| 11, 18, 21, 27 | Resveratrol is a potential cancer chemopreventive agent |
|
| |||
| [ |
| 10 | Resveratrol blocks the aryl hydrocarbon receptor and has beneficial effects against some types of tumors |
|
| |||
| [ |
| 10, 50, 100, 150 | The anticancer effect of resveratrol is via BCL-2 and NF |
|
| |||
| [ |
| 2.5, 5, 10, 20, 40 | The anticancer effect of resveratrol is via p53 |
|
| |||
| [ |
| 0.1–1000 | The anticancer effect of resveratrol is via inhibiting ribonuclease reductase |
|
| |||
| [ |
| 0.3–30 | Reactive oxygen species and arachidonic acid might be involved in the control of 3T6 fibroblast growth by resveratrol |
|
| |||
| [ |
| 0.1, 1.0 and 10.0 |
|
|
| |||
| [ |
| 0–500 | Resveratrol stimulates Sir2, thus increasing DNA stability and extending lifespan |